Building on these results, the aim of the study was to evaluate the activity of neratinib in association with capecitabine in LM from HER2-positive BC after the failure of multiple lines of treatment, including trastuzumab-based therapy, within a compassionate program. The gene discussed is ERBB2; the disease is breast cancer.